

COVID, uncertainty and clinical trials

Joaquim J. Ferreira




Common challenge

To be as close to the "truth" as possible





PD PROGRESSION





HYPOSMIA


- Well documented in PD patients
- Very sensitive for PD but not specific:
 - Alzheimer's disease, Multi-system atrophy, ALS



 Not PSP, restless legs syndrome, vascular parkinsonism, and essential tremor



Typical symptoms of COVID-19





The Majority of Infections are Mild Seriousness of symptoms 80.9% 13.8% 4.7% MILD SEVERE CRITICAL Like flu, stay at home Hospitalization Intensive care study of 44,672 confirmed cases in Mainland China informationisbeautiful sources: China Centre for Disease Control & Prevention, Statista



Table 1. Clinical Characteristics of Patients With COVID-19

JAMA Neurology | Original Investigation

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li, MD, PhD; Bo Hu, MD, PhD

	No. (%)							
Characteristic	Total (N = 214)	Severe (n = 88)	Nonsevere (n = 126)	P value ^a				
Age, mean (SD), y	52.7 (15.5)	58.2 (15.0)	48.9 (14.7)					
Vervous system symptoms								
Any	78 (36.4)	40 (45.5)	38 (30.2)	.02				
CNS	53 (24.8)	27 (30.7)	26 (20.6)	.09				
Dizziness	36 (16.8)	17 (19.3)	19 (15.1)	.42				
Headache	28 (13.1)	15 (17.0)	13 (10.3)	.15				
Impaired consciousness	16 (7.5)	13 (14.8)	3 (2.4)	<.001				
Acute cerebrovascular disease	6 (2.8)	5 (5.7)	1 (0.8)	.03				
Ataxia	1 (0.5)	1 (1.1)	0	NA				
Seizure	1 (0.5)	1 (1.1)	0	NA				
PNS	19 (8.9)	7 (8.0)	12 (9.5)	.69				
Impairment								
Taste	12 (5.6)	3 (3.4)	9 (7.1)	.24				
Smell	11 (5.1)	3 (3.4)	8 (6.3)	.34				
Vision	3 (1.4)	2 (2.3)	1 (0.8)	.37				
Nerve pain	5 (2.3)	4 (4.5)	1 (0.8)	.07				
skeletal muscle injury	23 (10.7)	17 (19.3)	6 (4.8)	<.001				





"Anosmia, in particular, has been seen in patients ultimately testing positive for the coronavirus with no other symptoms... anosmia, hyposmia, and dysgeusia in the absence of other respiratory disease such as allergic rhinitis, acute rhinosinusitis, or chronic rhinosinusitis should alert physicians to the possibility of COVID-19 infection and warrant serious consideration for self-isolation and testing of these individuals," the AAO-HNS said in a statement on the proposal.



100 years medical mystery



Spanish flu, influenza epidemic

1917 to 1920

Encephalitis lethargica, "sleeping sickness", "sleepy sickness" or von Economo Encephalitis

1917 to 1930

Post-encephalitic Parkinsonism

1917 -

Patients fill an emergency hospital in Camp Funston, Kan., during the 1918 influenza epidemic. **D** OTIS HISTORICAL ARCHIVES NAT'L MUSEUM OF HEALTH & MEDICINE





OXFORD MEDICAL PUBLICATIONS

ENCEPHALITIS LETHARGICA ITS SEQUELAE AND TREATMENT

BY CONSTANTIN VON ECONOMO

PROFESSOR OF PSYCHIATRY AND NEUROLOGY IN THE UNIVERSITY OF VIENNA

TRANSLATED AND ADAPTED BY

K. O. NEWMAN, M.D. PATHOLOGIST TO THE OXFORD COUNTY AND CITY MENTAL HOSPITAL OXFORD

With 21 Illustrations

OXFORD UNIVERSITY PRESS LONDON : HUMPHREY MILFORD 1931



SYMPTOM	Per	Cent of	Total 20	Cases 30	in v 40	hich 50		ed Syr 70	nptom 60	was 90	Present 100
PARALYSIS (ALL TOURS) FEVER								_		-	
CONSTIPATION	=				_						
Cona Prosis	-										
ASTHEMIA	_										
HEADACHE	-										
Aphasia Diplopia	_				_				_		1000
TREMORS	-		_		_						
STRABISMUS VERTIGO	-		_			_			-		
BLURRED VISION	-										
FACIAL PARALYSIS MUSCULAR RIGIDITY	-							-8			
DYSPHACIA			_				-	-			
BABINSKI'S SIGN											
VOMITING	=	_			_						
MUSCULAR PAINS			_								
SWEATING KERNIC'S SIGN	-		-	_							
RICIDITY OF NECK											1.75.46
CHOREIC MOVENENTS SKIN ERUPTIONS			ter.								

Fig. 37.2. Enacephalitis lethargica symptomatology. (Reproduced from Smith, 1921.)

von Economo classified acute encephalitis lethargica into 3 forms:

somnolent-ophthalmoplegic hyperkinetic amyostatic-akinetic

psychiatric manifestations changes in mood, feelings of euphoria, increased sexual drive, hallucinations, and excessive puns, joviality, and silliness

Smith HF (1921). Epidemic encephalitis (encephalitis lethargica, Nona): report of studies conducted in the United States. Public Health Rep 36: 207–242.







Experimental studies of the influenza hypothesis for encephalitis lethargica (EL)

Study	Conclusions						
Gamboa et al. (1974)	Influenza antigens detected in hypothalamus and midbrain in 6 PEP but no PD patients						
Marttila et al. (1977a)	No difference between 23 PEP and 421 PD controls for antibodies to influenza strain PR/8/34						
Marttila et al. (1977b)	No difference between 20 PEP and 55 PD and controls in antibodies to strains PR/8/24 and Sw/1976						
Elizan et al. (1989)	Negative immunostains for several flu strains in 1 acute EL and 1 PEP brain						
Isocson et al. (1995)	No influenza RNA in 7 PEP patients						
McCall et al. (2001)	mRNA of β ₂ -microglobulin but not influenza in brains of EL and PEP patients						
Lo et al. (2003)	mRNA of β-actin but not influenza in 8 EL brains						

aetiologies:

H1N1 cause / trigger / susceptibility ?

environmental (toxicological) infectious (viral, bacterial, etc.) auto-immunity

post-infectious autoimmune disorder Sydenham's chorea anti-NMDA receptor encephalitis

Modified from McCall et al. (2008).

McCall S, Vilensky JA, Gilman S et al. (2008). The relation- ship between encephalitis lethargica and influenza: a crit- ical analysis. J Neurovirol 14: 177–185.



HISTORICAL NEUROLOGY

The centennial lesson of encephalitis lethargica

Bart Lutters, BSc, Paul Foley, PhD, and Peter J. Koehler, MD, PhD Neurology^{*} 2018;90:563-567. doi:10.1212/WNL.000000000005176 **Correspondence** Dr. Koehler pkoehler@neurohistory.nl


von Economo clinicopathologic findings

+++ upper midbrain and substantia nigra

subcortical sleep-regulating center

10% insomnia

Figure von Economo's sleep-regulating center: First published in 1926




²⁸The sleep-regulating center is located at the transition between the diencephalon and mesencephalon (dotted line). The horizontal lines indicate the location of lesions resulting in somnolence. The diagonal lines denote the location of lesions resulting in insomnia.



von Economo clinicopathologic findings

+++ upper midbrain and **substantia nigra**





Arvid Carlsson

Oleh Go Hornykiewicz

George Cotzias



chronic phase of encephalitis lethargica

developed 1 to 5 years after the acute phase

one case 45 years



Awakenings, Oliver Sacks' 1973 book Movie 1990



kinesia paradoxical





2:00



Case Report

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2



Takeshi Moriguchi^{a,*}, Norikazu Harii^b, Junko Goto^a, Daiki Harada^a, Hisanori Sugawara^a, Junichi Takamino^a, Masateru Ueno^a, Hiroki Sakata^a, Kengo Kondo^a, Natsuhiko Myose^a, Atsuhito Nakao^c, Masayuki Takeda^d, Hirotaka Haro^e, Osamu Inoue^f, Katsue Suzuki-Inoue^g, Kayo Kubokawa^h, Shinji Ogiharaⁱ, Tomoyuki Sasaki^g, Hiroyuki Kinouchi^j, Hiroyuki Kojin^k, Masami Ito^k, Hiroshi Onishi^l, Tatsuya Shimizu^l, Yu Sasaki^l, Nobuyuki Enomoto^m, Hiroshi Ishiharaⁿ, Shiomi Furuya^k, Tomoko Yamamoto^k, Shinji Shimada^o

coronaviruses (OC-43, 229E, MERS and SARS) can invade the central nervous system and cause neurological pathologies

SARS-CoV-2 infection causes

headache, dizziness, myalgia and anosmia

cases encephalopathy, encephalitis, necrotising haemorrhagic encephalopathy, stroke, epileptic seizures, rhabdomyolysis and Guillain-Barre syndrome



ACCEPTED MANUSCRIPT

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings 3

Ross W Paterson, Rachel L Brown, Laura Benjamin, Ross Nortley, Sarah Wiethoff, Tehmina Bharucha, Dipa L Jayaseelan, Guru Kumar, Rhian E Raftopoulos, Laura Zambreanu ... Show more

Author Notes

Brain, awaa240, https://doi.org/10.1093/brain/awaa240 Published: 08 July 2020 Article history ▼

 Table 1 Summary of clinical features of 43 patients with neurological complications of COVID-19

Cases	Age, median [range]; %male	Days of COVID-19 infection before neurological presentation, median [range]	Main clinical features	Results of note	% Naso- pharyhgeal SARS-CoV-2 PCR+	CSF or brain SARS-CoV-2 PCR+ (x/number tested)	Treatment	Clinical outcome
Encephalopathy (delirium/psychosis) $(n = 10)^{a}$	57.5 [39–72]; 40	4.5 [-4 to +21]	Delirium; psychosis	Acellular CSF (6/6); non-specific MRI changes (3/10)	80 (8/10)	(0/0)	Supportive (9/10); steroids 1/10	Complete recovery (7/10); partial (2/10)
Inflammatory CNS syndromes (para- /post- infectious) (n = 12) ^a	53 [27–66]; 33	9 [-6 to +27]	Reduced consciousness (7/12); UMN signs (10/12)	Abnormal CSF (6/11) Abnormal MRI (11/12)	67 (8/12)	(0/7)	Corticosteroids (10/12); IVIG (3/12)	Recovery: complete (1/12); partial (10/12); none (death 1/12)
Stroke (<i>n</i> = 8) ^a	62.5 [27–85]; 75	8[-2 to +22]	Large vessel ischaemic stroke	4/8 PE 6/6 High D–dimer	75 (6/8)	NA	Low molecular weight heparin (7/8); apixaban (1/8)	Incomplete recovery (7/8); death (1/8)
Peripheral syndromes (n = 8)							
GBS (n = 7)	57 [20–63]; 100	13 [-1-21]	Cranial and peripheral neuropathy		43 (3/7)	NT	IVIG (7/7)	Incomplete recovery (5/7 GBSDS 2)
Plexopathy $(n = 1)$	60; 100	14	Painless weakness		100 (1/1)	NT	IV steroids (1/1)	Incomplete recovery (1/1)
Miscellaneous and uncharacterized (<i>n</i> = 5)	20 [16–40]; 40	10 [6–26]	Raised ICP; seizures; myelitis	Abnormal CSF (2/4) Abnormal MRI brain (4/5)	60 (3/5)	(0/1)	Varied (AED; steroids (1/5); tLP)	Recovery complete (1/5); partial (3/5); nil (1/5)



Why is important to recognize the unknown / uncertainty?

6 months of data is short

delayed onset manifestations?

post-infectious neurologic disorders?

association hyposmia + sleep + behaviour !

reasons to be prudent



Hydroxychloroquine story?






Liu et al. *Cell Discovery* (2020)6:16 https://doi.org/10.1038/s41421-020-0156-0 Cell Discovery www.nature.com/celldisc

CORRESPONDENCE

Open Access

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Jia Liu¹, Ruiyuan Cao², Mingyue Xu^{1,3}, Xi Wang¹, Huanyu Zhang^{1,3}, Hengrui Hu^{1,3}, Yufeng Li^{1,3}, Zhihong Hu^{1,3}, Wu Zhong² and Manli Wang¹





Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial *

Philippe Gautret^{a,b,5}, Jean-Christophe Lagier^{a,c,5}, Philippe Parola^{a,b}, Van Thuan Hoang^{a,b,d}, Line Meddeb^a, Morgane Mailhe^a, Barbara Doudier^a, Johan Courjon^{e,f,g}, Valérie Giordanengo^h, Vera Esteves Vieira^a, Hervé Tissot Dupont^{a,c}, Stéphane Honoré^{i,j}, Philippe Colson^{a,c}, Eric Chabrière^{a,c}, Bernard La Scola^{a,c}, Jean-Marc Rolain^{a,c}, Philippe Brouqui^{a,c}, Didier Raoult^{a,c,*}

Outcome

Primary endpoint was virological clearance at day-6 postinclusion.




Fig. 2. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithromycin combination, and in COVID-19 control patients.




Table 1 Characteristics of the study population

	Age (years)			Male gender		Clinical status			Time between onset of symptoms and inclusion (days)			
	$Mean \pm SD$	t	p-value	n (%)	p-value	Asymptomatic	URTI	LRTI	p-value	$Mean \pm SD$	t	p-value
Hydroxychloroquine treated patients (N=20)	51.2 ± 18.7	-1.95	0.06	9 (45.0)	0.65	2 (10.0)	12 (60.0)	6 (30.0)	0.30	4.1 ± 2.6	-0.15	0.88
Control patients (N=16)	37.3 ± 24.0			6 (37.5)		4 (25.0)	10 (62.5)	2 (12.5)		3.9 ± 2.8		
All patients (36)	45.1 ± 22.0			15 (41.7)		6 (16.7)	22 (61.1)	8 (22.2)		4.0 ± 2.6		

URTI: upper tract respiratory infection, LRTI: lower tract respiratory infection

6 hydroxychloroquine- treated patients were lost during the follow-up (23%)

Fig. 1. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine and in COVID-19 control patients.



Hydroxychloroguine or chloroguine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Mandeep R Mehra, Sapan S Desai, Frank Ruschitzka, Amit N Patel

Summary

Interpretat

a macro

Background Hydroxychloroquine or chloroquine, often in combination with a second-generation m widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although used for approved indications such as autoimmune disease or malaria, the safety and bene regimens are poorly evaluated in COVID-19.

Methods We did a multinational registry analysis of the use of hydroxychloroquine macrolide for treatment of COVID-19. The registry comprised data from 671 hospin s in s patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory n Patients who received one of the treatments of interest within 48 h of diagon included in groups (chloroquine alone, chloroquine with a macrolide, hydroxychlor macrolide), and patients who received none of these treatments formed control gr the treatments of interest was initiated more than 48 h after diagnosis of ile they we as well as patients who received remdesivir, were excluded. The main outco st were in-hospital mortality of int and the occurrence of de-novo ventricular arrhythmias (stained or ed ventricular tachycardia or ventricular fibrillation).

Findings 96032 patients (mean age 53.8 years, 46.3% women) period and met the inclusion criteria. Of the chloroquine, 3783 received chloroquine with macro hydroxychloroquine with a macrolide) and 1 pati hospital. After controlling for multiple four cardiovascular disease and its risk fac diabetes and baseline disease severity), w mpared with (18.0%; hazard ratio 1.335, 95% 1.22 18–1 · 531), chloroquine (16 · 4%; 1 · 365, independently associated n an increased h s; 2·36 hydroxychloroquine (6 1 2 chloroguine (4.3%; independently associate an incr d risk of de-novo ventricular arrhythmia during hospitalisation.

oquine with thout a ntinents. We included g for SARS-CoV-2. of four treatment ine alone, or hydroxychloroquine with a Patients for whom one of on mechanical ventilation.

herally

f th

nide, are b

OVID-19 were hospitalised during the study were in the treatment groups (1868 received eived hydroxychloroquine, and 6221 received e control group. 10698 (11.1%) patients died in sex, race or ethnicity, body-mass index, underlying erlying lung disease, smoking, immunosuppressed condition, ortality in the control group (9.3%), hydroxychloroquine 457), hydroxychloroquine with a macrolide (23.8%; 1.447, 1.368–1.531), chloroquine with a macrolide (22.2%; 1.368, 1.273–1.469) were each f in-hospital mortality. Compared with the control group (0.3%), • 935–2 · 900, hydroxychloroquine with a macrolide (8 · 1%; 5 · 106, 4 · 106–5 · 983), $0-4 \cdot 596$), and chloroquine with a macrolide (6 $\cdot 5\%$; 4 $\cdot 011$, 3 $\cdot 344-4 \cdot 812$) were

We w firm a benefit of hydroxychloroquine or chloroquine, when used alone or with unabk on ir spital outcomes for COVID-19. Each of these drug regimens was associated with decreased eased frequency of ventricular arrhythmias when used for treatment of COVID-19.

patiei

e, 3016

22,2020 fe whe ttps://doi.org/10.1016/ reatment 50140-6736(20)31180-6 This online publication has been

d Onlin

corrected. The corrected version first appeared at thelancet.com on May 29, 2020

℈ℛ⅍ℿ

See Online/Comment https://doi.org/10.1016/ 50140-6736(20)31174-0

Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School Boston, MA, USA (Prof M R Mehra MD): Surgisphere Corporation, Chicago, IL, USA (S S Desai MD) **University Heart Center** University Hospital Zurich, Zurich, Switzerland (Prof F Ruschitzka MD): Department of Biomedica Engineering, University of Utah, Salt Lake City, UT, USA (A N Patel MD); and HCA Research Institute, Nashville TN, USA (A N Patel) Correspondence to

Prof Mandeep R Mehra, Brighan and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA 02115, USA mmehra@bwh.harvard.edu

in-hospita

yey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital. Funding William




Ongoing trials on COVID-19

Beatrice Mainoli Tiago Machado Gonçalo S Duarte Luísa Prada Nilza Gonçalves Joaquim J Ferreira João Costa

- 30 March 2020
 - WHO International Clinical Trials Registry Platform (ICTRP) contains the trial registration datasets provided by 17 clinical trial registries
 - National clinical trials registries
 - ClinicalTrials.gov, EU Clinical Trials Register, Chinese Clinical Trial Register
- Independent trials selection and data extraction





Instituto

de Medicina

Molecular


FACULDADE DE **MEDICINA** LISBOA

MM

F




RESULTS - COVID-19 treatment (n=331)





RESULTS - COVID-19 pharmacotherapy (n=163)





- Patients at largest risk of death are not being prioritized in trials
 - High baseline risk means that smaller treatment effects would be more easily detected
- 15% are **single-arm**
 - CFR change considerably over time
 - Trials using historical controls will likely lead to more false-positive findings
- 59% are **not multicenter**
 - single-center trials are more prone to bias and tend to provide larger effects
 - Particularly true in the critical care setting, where many positive single-center trials have been contradicted by subsequent multicenter trials
- Lack of hard and more pragmatic endpoints
- Many treatment trials are *a priori* already deemed to fail
 - N° **trials powered** to detect a difference \geq 50% between treatment groups



- Persisting on the path of "futile" trials will likely only lead to no informative trials and no gain in knowledge
- Urgent need for a global high-quality COVID-19 trials and observational data registry




so little time, so much work, so much waste

João Costa



be a humble researcher

After 100 years standard of treatment is the same



Leaflets to the people Rio de Janeiro, 1918

quinine for prevention!



be a humble researcher

We need pragmatic trials feasible to be conducted in difficult clinical circunstances

Hard outcomes

Adaptive designs (therapeutic arms, dose, therapeutic associations, futility trials)

Registries of clinical trials and long term observational data



be a humble researcher

At least lets learn for the next pandemic ...



COVID, uncertainty and clinical trials

Joaquim J. Ferreira